AdCLD-CoV19
AdCLD-CoV19 is a COVID-19 vaccine candidate developed by Cellid Co,[1][2][3] a company from South Korea.[4]
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Viral vector |
| Clinical data | |
| Routes of administration | Intramuscular |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom. |
|
.svg.png.webp){kind=small} COVID-19 portal |
References
- "Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers". ClinicalTrials.gov. 14 December 2020. NCT04666012. Retrieved 23 March 2021.
- Chan-Hyuk, Kim (10 December 2020). "LG Chem pushes for Covid-19 vaccine CMO deal". Korea Biomedical Review. Retrieved 22 August 2021.
- Chan-hyuk, Kim (11 August 2021). "Covid-19 vaccine trials stalled by rare chance to get licensed vaccines". Korea Biomedical Review. Retrieved 22 August 2021.
- Cellid Co Ltd, Company Profile and News, Bloomberg Markets.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.